
  
    
      
        
        Hypertension_NNP is_VBZ common_JJ in_IN affluent_JJ societies_NNS and_CC a_DT major_JJ risk_NN factor_NN for_IN heart_NN disease_NN ._.
        In_IN Canada_NNP ,_, hypertension_NN is_VBZ the_DT leading_VBG primary_JJ diagnosis_NN for_IN patient_NN visits_NNS to_TO physicians_NNS '_POS
        offices_NNS ._. Beyond_IN recommending_VBG lifestyle_NN changes_NNS such_JJ as_IN losing_VBG weight_NN ,_, quitting_VBG smoking_NN ,_, and_CC
        lowering_VBG salt_NN and_CC alcohol_NN intake_NN ,_, prescription_NN drugs_NNS are_VBP indicated_VBN in_IN many_JJ patients_NNS ._. As_IN a_DT
        consequence_NN ,_, antihypertensive_JJ drugs_NNS are_VBP the_DT leading_VBG category_NN of_IN prescription_NN drugs_NNS in_IN
        Canada_NNP ,_, accounting_NN for_IN 20_CD %_NN of_IN prescription_NN drug_NN sales_NNS ._.
        Several_JJ classes_NNS of_IN drugs_NNS are_VBP available_JJ for_IN treatment_NN ,_, including_VBG diuretics_NNS ,_, ACE_NNP
        inhibitors_NNS ,_, and_CC calcium_NN channel_NN blockers_NNS ._. First-line_NNP treatment_NN with_IN thiazide_NN diuretics—the_NN
        oldest_JJS and_CC by_IN far_RB the_DT cheapest_JJS drug_NN class—has_NNS been_VBN shown_VBN in_IN randomized_JJ trials_NNS to_TO reduce_VB
        serious_JJ cardiovascular_JJ morbidity_NN and_CC mortality_NN with_IN benefits_NNS at_IN least_JJS as_RB great_JJ as_IN
        first-line_JJ treatment_NN with_IN other_JJ drug_NN classes_NNS ._.
        Steve_NNP Morgan_NNP and_CC colleagues_NNS set_VBN out_IN to_TO examine_VB whether_IN prescribing_VBG practices_NNS were_VBD in_IN
        accordance_NN with_IN this_DT evidence_NN ._. They_PRP analyzed_VBD administrative_JJ claims_NNS data_NNS from_IN a_DT public_JJ drug_NN
        plan_NN for_IN seniors_NNS (_( residents_NNS of_IN age_NN 65_CD and_CC older_JJR )_) to_TO determine_VB trends_NNS in_IN first-line_JJ
        hypertension_NN drug_NN use_NN ._. During_IN the_DT period_NN from_IN 1993_CD to_TO 2000_CD ,_, over_IN 82_CD ,_, 000_CD seniors_NNS were_VBD
        identified_VBN as_IN new_JJ users_NNS of_IN hypertension_NN drugs_NNS ._. Less_RBR than_IN a_DT third_JJ of_IN these_DT patients_NNS received_VBD
        thiazides_NNS (_( alone_RB or_CC as_IN part_NN of_IN a_DT combination_NN regimen_NN )_) as_IN a_DT first-line_JJ treatment_NN ._.
        The_DT share_NN of_IN new_JJ patients_NNS receiving_VBG a_DT thiazide_NN increased_VBD over_IN the_DT study_NN period_NN ,_, but_CC did_VBD
        not_RB exceed_VB 45_CD %_NN at_IN any_DT point_NN ._. Women_NNP were_VBD more_RBR likely_JJ than_IN men_NNS ,_, and_CC older_JJR patients_NNS were_VBD more_RBR
        likely_JJ than_IN younger_JJR ones_NNS ,_, to_TO receive_VB thiazides_NNS ._. Comorbidities_NNP also_RB influenced_VBD prescribing_VBG
        practices_NNS :_: patients_NNS without_IN concurrent_JJ diagnoses_NNS were_VBD more_RBR likely_JJ to_TO receive_VB thiazides_NNS ._.
        While_IN for_IN some_DT comorbidities_NNS (_( such_JJ as_IN previous_JJ acute_JJ myocardial_NN infarction_NN )_) evidence_NN
        suggested_VBD that_IN there_EX were_VBD good_JJ reasons_NNS to_TO prescribe_VB drugs_NNS other_JJ than_IN thiazides_NNS ,_, no_DT such_JJ
        evidence_NN existed_VBD for_IN many_JJ of_IN the_DT other_JJ conditions_NNS that_WDT nevertheless_RB were_VBD associated_VBN with_IN
        lower_JJR prescription_NN of_IN thiazides_NNS ._.
        Changes_NNS in_IN drug_NN availability_NN and_CC existing_VBG evidence_NN during_IN the_DT period_NN studied_VBN make_VB it_PRP
        difficult_JJ to_TO calculate_VB the_DT exact_JJ extent_NN to_TO which_WDT thiazides_NNS were_VBD under-prescribed_JJ ._. However_RB ,_,
        the_DT study_NN shows_VBZ that_IN many_JJ patients_NNS received_VBD drugs_NNS that_WDT had_VBD previously_RB been_VBN found_VBN to_TO be_VB no_DT
        better_JJR at_IN treating_VBG hypertension_NN than_IN much_RB cheaper_JJR alternatives_NNS ._. Drug_NN prices_NNS changed_VBN over_IN
        the_DT study_NN period_NN as_IN well_RB ,_, but_CC even_RB comparing_VBG the_DT lowest_JJS price_NN for_IN any_DT of_IN the_DT alternatives_NNS
        to_TO thiazides_NNS ,_, $_$ 0_CD ._. 34_CD per_IN day_NN ,_, with_IN the_DT constant_JJ cost_NN of_IN less_JJR than_IN $_$ 0_CD ._. 01_CD per_IN day_NN for_IN a_DT
        thiazide_NN makes_VBZ it_PRP clear_JJ that_IN a_DT lot_NN of_IN money_NN was_VBD wasted_VBN ._.
        On_IN a_DT more_RBR positive_JJ note_NN ,_, prescription_NN of_IN thiazides_NNS as_IN a_DT first-line_JJ therapy_NN rose_VBD over_IN the_DT
        study_NN period—from_NN 25_CD %_NN to_TO 42_CD %_NN in_IN patients_NNS without_IN comorbidities_NNS ._. Most_JJS of_IN the_DT increase_NN
        occurred_VBD shortly_RB after_IN a_DT specific_JJ local_JJ education_NN campaign_NN ._. This_DT suggests_VBZ that_WDT repeated_VBD
        targeting_VBG of_IN prescribing_VBG physicians—many_NN of_IN whom_WP receive_VB regular_JJ marketing_NN material_NN from_IN
        pharmaceutical_JJ companies_NNS and_CC subscribe_VB to_TO the_DT general_JJ view_NN that_IN newer_JJR drugs_NNS are_VBP better—with_NN
        current_JJ evidence-based_JJ information_NN should_MD be_VB considered_VBN ._.
        One_CD of_IN the_DT most_RBS influential_JJ studies_NNS comparing_VBG antihypertensive_JJ drugs_NNS ,_, the_DT ALLHAT_NNP study_NN ,_,
        also_RB supported_VBD the_DT use_NN of_IN thiazides_NNS as_IN first-line_JJ drugs_NNS ._. ALLHAT_NNP was_VBD published_VBN in_IN 2003_CD ,_, and_CC
        its_PRP$ results_NNS widely_RB publicized_VBN ._. According_VBG to_TO Steve_NNP Morgan_NNP ,_, “ Anecdotal_NNP evidence_NN suggests_VBZ that_IN
        ALLHAT_NNP has_VBZ had_VBN an_DT influence_NN on_IN prescription_NN practices_NNS ,_, but_CC I_PRP am_VBP not_RB aware_JJ of_IN a_DT large-scale_JJ
        analysis_NN yet_RB ._.”
      
    
  
